Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

SYHX 1901

Next Previous
Drug Profile

SYHX 1901

Alternative Names: SYHX-1901

Latest Information Update: 06 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator CSPC Ouyi Pharmaceutical
  • Class Anti-inflammatories; Antirheumatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase inhibitors; Syk kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Plaque psoriasis; Vitiligo
  • No development reported Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 30 Apr 2025 CSPC Ouyi Pharmaceutical plans a phase III trial for Plaque psoriasis (PO, Tablets) in June 2025 (NCT06943950)
  • 20 Aug 2024 CSPC Ouyi Pharmaceutical plans a phase II trial for Alopecia Areata in November 2024 (NCT06562894)
  • 28 Jun 2024 No recent reports of development identified for phase-I development in Rheumatoid-arthritis(In volunteers) in China (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top